Colorectal Cancer - KOL Insight

In what settings will the bevacizumab+Taiho Oncology's Lonsurf combination bring value and how might Hutchmed's late-stage oral therapy fruquintinib disrupt the anti-VEGF sector? What clinical advantages do KOLs identify for anti-EGFR+kinase inhibitor combinations? What underpins KOLs' enthusiasm about Agenus' Balstilimab+botensilimab combination in non-liver metastatic MSS patients? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (8)

Research objectives (4)

Marketed products

Anti-VEGF therapies (10)

• Key insights summary (10)
  • Avastin (bevacizumab; Roche/Chugai)
  • Zaltrap (ziv-aflibercept; Regeneron/Bayer/Sanofi)
  • Cyramza (ramucirumab; Lilly) (8)

Anti-EGFR therapies (12)

• Key insights summary (12)
  • Erbitux (cetuximab; Lilly/Merck Group) (1)
  • Vectibix (panitumumab; Amgen) (9)

Oral multikinase inhibitors (7)

• Key insights summary (7)
  • Stivarga (regorafenib; Bayer) (5)

HER-2 inhibitors (8)

• Key insights summary (8)
  • Tukysa (tucatinib; Array BioPharma/Merck & Co./Seagen) (6)

PD-1/CTLA-4 immunotherapies (10)

• Key insights summary (10)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)
  • Yervoy (ipilimumab; BMS) (8)

BRAF inhibitors (6)

• Key insights summary (6)
  • Encorafenib (Braftovi; Array BioPharma)
  • Binimetinib (Mektovi; Array BioPharma) (4)

Late-stage pipeline drugs (73)

• Immunotherapies (7)
  • Key insights summary (2)
  • Atezolizumab (Tecentriq; Roche/Genentech)
  • Futuximab + modotuximab (Sym004; Symphogen) (5)
• Anti-LAG3/PD-1 combinations (5)
  • Key insights summary (2)
  • Opdualag (nivolumab + relatlimab; Bristol Myers Squibb)
  • Pembrolizumab + favezelimab (MK-4280A; Merck & Co.) (3)
• ErbB-2 receptor targeted FDC (3)
  • Phesgo (hyaluronidase/pertuzumab/trastuzumab; Roche) (3)
• Cancer vaccines (8)
  • Key insights summary (2)
  • OncoVAX (autologous cancer vaccine; Vaccinogen) (1)
  • GRANITE (Gritstone bio) (5)
• Anti-VEGF therapies (8)
  • Key insights summary (2)
  • Zanzalintinib (oral TKI targeting VEGF; Exelixis)
  • Fruquintinib (HUTCHMED) (6)
• KRAS inhibitors (7)
  • Key insights summary (2)
  • Lumakras (sotorasib; Amgen)
  • Krazati (adagrasib; Mirati Therapeutics) (5)
• PARP inhibitors (7)
  • Key insights summary (2)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (5)
• Cyclooxygenase/ornithine decarboxylase inhibitors (4)
  • Key insights summary (2)
  • Flynpovi (eflornithine + sulindac; Panbela Therapeutics) (2)
• Other pipeline drugs (7)
  • Key insights summary (2)
  • Modufolin (arfolitixorin; Isofol Medical)
  • Vascepa (ethyl eicosapentaenoic acid; Amarin) (5)
• Mid/early-stage prospects (17)
  • HER-2 inhibitors (2)
  • Enhertu (DTX-d/trastuzumab deruxtecan; Daiichi Sankyo and AstraZeneca) (6)
  • Novel checkpoint (CTLA-4/PD-1/TIGIT) inhibitors (2)
  • Tiragolumab (Roche)
  • Domvanalimab (Gilead)
  • Vibostolimab (Merck) (3)
  • Botensilimab/balstilimab (Agenus) (4)

Future outlook (10)

• Key insights summary (10)
  • CRC will see more personalised treatment by defining patient subsets based on molecular profiling (8)

Appendix (5)

• KOL details (5)